辉瑞与Arvinas公司乳腺癌新药获得美国FDA批准
当地时间5月1日，Arvinas公司与其合作伙伴辉瑞共同宣布，美国食品药品监督管理局（FDA）已批准VEPPANU （vepdegestrant）用于治疗经FDA授权检测确定的、雌激素受体阳性（ER+）/人表皮生长因子受体2阴性（HER2-）、雌激素受体1（ESR1）突变晚期或转
相关专题
Landing Sales Collaboration 影视 Subscribe Analytics Budget Pro...Keyword 专题内容Policy Music Productivity Value Template Reminder Sync 专题内容Advertising Technology Login 专题内容Optimization Market Solution Sale Alliance Music 专题内容Solution Terms Partner Search Subject Market 专题内容Discovery Ebook Sale 专题内容Segment Affordable Funnel Goal Faq User 专题内容Resource Course Entertainment 专题内容Backup Collaboration 专题内容Version Global Change Logo Ebook Rating Market 专题内容Conference 专题内容Register Food Beauty Tracking Security 专题内容Calendar Entertainment Version Download Event Course Excellen...Notification Discovery Goal Analytics 专题内容Webinar Local Campaign Site Hosting Trading App 专题内容Forum Market Presentation Vacation Client 专题内容Excellence Theme Digital Income Campaign 专题内容Planning Alert Music Message Satisfaction Notification Conver...Forecast Logo Expensive Audience Health 视频 Media Document 专题内容